Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Recommendation of “Hold” from Brokerages

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has received a consensus recommendation of “Hold” from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $17.86.

A number of equities research analysts have weighed in on the company. Truist Financial assumed coverage on Y-mAbs Therapeutics in a research report on Friday. They set a “buy” rating and a $21.00 price target on the stock. HC Wainwright increased their price target on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, May 13th. BMO Capital Markets boosted their price objective on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the stock an “outperform” rating in a report on Monday, March 4th. Finally, Canaccord Genuity Group increased their target price on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a report on Monday, March 4th.

Insider Activity at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 7,351 shares of the company’s stock in a transaction that occurred on Thursday, May 23rd. The stock was sold at an average price of $13.00, for a total transaction of $95,563.00. Following the sale, the insider now directly owns 232,681 shares of the company’s stock, valued at approximately $3,024,853. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Bo Kruse sold 31,371 shares of Y-mAbs Therapeutics stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $12.07, for a total transaction of $378,647.97. Following the completion of the transaction, the chief financial officer now directly owns 210,877 shares of the company’s stock, valued at approximately $2,545,285.39. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Thomas Gad sold 7,351 shares of the company’s stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $13.00, for a total value of $95,563.00. Following the transaction, the insider now directly owns 232,681 shares in the company, valued at approximately $3,024,853. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 99,444 shares of company stock valued at $1,203,925. Corporate insiders own 21.50% of the company’s stock.

Institutional Trading of Y-mAbs Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of YMAB. Acadian Asset Management LLC increased its position in Y-mAbs Therapeutics by 24.0% during the 3rd quarter. Acadian Asset Management LLC now owns 811,261 shares of the company’s stock valued at $4,420,000 after purchasing an additional 157,173 shares during the period. GSA Capital Partners LLP increased its holdings in Y-mAbs Therapeutics by 208.3% during the third quarter. GSA Capital Partners LLP now owns 137,299 shares of the company’s stock valued at $748,000 after buying an additional 92,765 shares during the period. Campbell & CO Investment Adviser LLC bought a new position in Y-mAbs Therapeutics in the fourth quarter worth approximately $562,000. Trexquant Investment LP lifted its holdings in Y-mAbs Therapeutics by 417.5% during the third quarter. Trexquant Investment LP now owns 76,585 shares of the company’s stock worth $417,000 after buying an additional 61,785 shares during the period. Finally, Los Angeles Capital Management LLC boosted its position in Y-mAbs Therapeutics by 17.3% during the 4th quarter. Los Angeles Capital Management LLC now owns 356,530 shares of the company’s stock valued at $2,432,000 after acquiring an additional 52,610 shares in the last quarter. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Price Performance

Shares of YMAB stock opened at $12.08 on Monday. The stock has a market capitalization of $530.07 million, a price-to-earnings ratio of -24.65 and a beta of 0.69. The company’s fifty day simple moving average is $13.07 and its two-hundred day simple moving average is $12.78. Y-mAbs Therapeutics has a 1 year low of $4.60 and a 1 year high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Tuesday, May 7th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). The firm had revenue of $19.93 million for the quarter, compared to the consensus estimate of $22.06 million. Y-mAbs Therapeutics had a negative return on equity of 21.40% and a negative net margin of 25.64%. Equities research analysts anticipate that Y-mAbs Therapeutics will post -0.45 EPS for the current year.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.